RE:Q for notableWith repect to pelareorep + atezolizumab (Tecentriq) in pancreatic cancer, if Roche were to license pelareorep or to obtain outright possession of pelareorep through the acquisition of ONCY, and were to then seek and obtain CBER marketing approval for this biologic-drug/biologic combination, Roche would gain 12 years of FDA market exclusivity for this "biologic-led" combinational product for use in pancreatic cancer.
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/combination-products-guidance-documents